MX2025013810A - Composicion para la prevencion o el tratamiento del dolor por cancer - Google Patents

Composicion para la prevencion o el tratamiento del dolor por cancer

Info

Publication number
MX2025013810A
MX2025013810A MX2025013810A MX2025013810A MX2025013810A MX 2025013810 A MX2025013810 A MX 2025013810A MX 2025013810 A MX2025013810 A MX 2025013810A MX 2025013810 A MX2025013810 A MX 2025013810A MX 2025013810 A MX2025013810 A MX 2025013810A
Authority
MX
Mexico
Prior art keywords
cancer pain
composition
preventing
optionally substituted
treating cancer
Prior art date
Application number
MX2025013810A
Other languages
English (en)
Spanish (es)
Inventor
Erika Kubo
Yoshiro Yamamura
Shoichi Shimada
Yukiko Yamamoto
Original Assignee
Maruishi Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharma filed Critical Maruishi Pharma
Publication of MX2025013810A publication Critical patent/MX2025013810A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2025013810A 2023-05-25 2025-11-19 Composicion para la prevencion o el tratamiento del dolor por cancer MX2025013810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023086153 2023-05-25
PCT/JP2024/018940 WO2024242158A1 (ja) 2023-05-25 2024-05-23 がん性疼痛予防又は治療用組成物

Publications (1)

Publication Number Publication Date
MX2025013810A true MX2025013810A (es) 2025-12-01

Family

ID=93589461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025013810A MX2025013810A (es) 2023-05-25 2025-11-19 Composicion para la prevencion o el tratamiento del dolor por cancer

Country Status (9)

Country Link
EP (1) EP4699608A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024242158A1 (cg-RX-API-DMAC7.html)
KR (1) KR20260016503A (cg-RX-API-DMAC7.html)
CN (1) CN121079089A (cg-RX-API-DMAC7.html)
AU (1) AU2024275598A1 (cg-RX-API-DMAC7.html)
IL (1) IL324153A (cg-RX-API-DMAC7.html)
MX (1) MX2025013810A (cg-RX-API-DMAC7.html)
TW (1) TW202508584A (cg-RX-API-DMAC7.html)
WO (1) WO2024242158A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459240A1 (fr) 1979-06-21 1981-01-09 Cm Ind Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent
DE69228017D1 (de) 1991-03-27 1999-02-11 Sanofi Sa Verwendung von 4-Amino-1-(2-Pyridyl)Piperidinen als 5-HT3-Agonisten zur Behandlung und Verhütung von serotoninergen Dysfunktionen
ES2960385T3 (es) * 2017-06-28 2024-03-04 Univ Osaka Tratamiento del dolor con agonista del receptor de serotonina-3

Also Published As

Publication number Publication date
TW202508584A (zh) 2025-03-01
EP4699608A1 (en) 2026-02-25
AU2024275598A1 (en) 2026-01-15
CN121079089A (zh) 2025-12-05
WO2024242158A1 (ja) 2024-11-28
IL324153A (en) 2025-12-01
JPWO2024242158A1 (cg-RX-API-DMAC7.html) 2024-11-28
KR20260016503A (ko) 2026-02-03

Similar Documents

Publication Publication Date Title
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
MY206521A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EA200401254A1 (ru) Комбинированное применение противоопухолевого производного индолопирролокарбазола и другого противоопухолевого агента
NZ528676A (en) Use of bisphosphonates in the treatment of bone metastases associated with prostate cancer
MXPA02001571A (es) Metodo de tratamiento para el cancer.
ZA200505273B (en) Novel compound
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
NO20004162D0 (no) Antitumor agens
KR930702975A (ko) 사이토킨 억제제
MX2025002491A (es) Composiciones farmaceuticas a base de inhibidores de la topoisomerasa-1 derivados del exatecan, y sus usos
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.
MX2023009166A (es) Derivados de quinoxalina y sus usos.
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
AU7950100A (en) 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
MX2024009608A (es) Compuestos heterociclicos y metodos de uso.
MX2025004725A (es) Derivados de las antraciclinas pnu y metodos de uso de los mismos
MXPA03005374A (es) Carbazoles antitumorales.
AU2002214320A1 (en) Imidazole derivatives, process for their preparation and their use
EP1330456B8 (en) N8,n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
IL147307A0 (en) Indolocarbazole alkaloid derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
YU43302A (sh) Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija
WO2001081315A3 (en) Amino-imidazole derivatives for treating cancer
MX2025005365A (es) Compuestos triciclicos